Demographic and clinicopathologic characteristics for patients with cancers with PI3K pathway mutations vs. wildtype in the entire cohort and in the KRAS G12R and non-G12R mutated subgroups are shown in Supplementary Tables S1, S2, and S3. The gene discussed is KRAS; the disease is cancer.